BioNexus Gene Lab Corp
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BioNexus Gene Lab Corp. | |
|---|---|
| /s/ Su-Leng Tan Lee | Dated: April 15, 2025 |
| Su-Leng Tan Lee | |
| Chief Executive Officer | |
| (Principal Executive Officer) | |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| /s/ Su-Leng Tan Lee | Dated: April 15, 2025 |
|---|---|
| Su-Leng Tan Lee | |
| Chief Executive Officer and Director | |
| (Principal Executive Officer) | |
| /s/ Su-Leng Tan Lee | Dated: April 15, 2025 |
| Su-Leng Tan Lee | |
| Acting Chief Financial Officer | |
| (Principal Financial and Accounting Officer) | |
| /s/ Chee Keong Yap | Dated: April 15, 2025 |
|---|---|
| Chee Keong Yap | |
| Director | |
| /s/ Jook Yuen Low | Dated: April 15, 2025 |
| Jook Yuen Low | |
| Director | |
| /s/ Muhammad Azrul bin Abdul Hamid | Dated: April 15, 2025 |
|---|---|
| Muhammad Azrul bin Abdul Hamid | |
| Director | |
| PART I FINANCIAL INFORMATION | Page | ||
|---|---|---|---|
| ITEM FINANCIAL STATEMENTS: | |||
| 1. | |||
| Report of Independent Registered Public Accounting Firm | F-2-F-3 | ||
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-4 to F-5 | ||
| Consolidated Statements of Operations and Comprehensive Income/(Loss) for the Year Ended December 31, 2024 and 2023 | F-6 | ||
| Consolidated Statements of Changes in Stockholders’ Equity for the Year Ended December 31, 2024 and 2023 | F-7 | ||
| Consolidated Statements of Cash Flows for the Year Ended December 31, 2024 and 2023 | F-8 to F-9 | ||
| Notes to the Consolidated Financial Statements | F-10 to F-30 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.